Brucellosis in low-income and middle-income countries

Current Opinion in Infectious Diseases

Volumn 26, Issue 5, 2013, Pages 404-412

  Rubach, Matthew P ^a   Halliday, Jo E B ^b   Cleaveland, Sarah ^b   Crump, John A ^a,c  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

brucellosis; epidemiology; neglected diseases; zoonoses

Indexed keywords

AMINOGLYCOSIDE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; CIPROFLOXACIN; COTRIMOXAZOLE; DOXYCYCLINE; GENTAMICIN; OFLOXACIN; RIFAMPICIN; STREPTOMYCIN; TETRACYCLINE DERIVATIVE;

ANEMIA; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTHRALGIA; ARTHRITIS; AZERBAIJAN; BACKACHE; BLOOD CULTURE; BRUCELLA MELITENSIS; BRUCELLOSIS; CHINA; DEVELOPING COUNTRY; DRUG TREATMENT FAILURE; ENZYME LINKED IMMUNOSORBENT ASSAY; HEPATOMEGALY; HUMAN; INCIDENCE; INFECTION CONTROL; IRAQ; JORDAN; KYRGYZSTAN; LATEX AGGLUTINATION TEST; LEUKOPENIA; MEXICO; MYALGIA; NONHUMAN; PACIFIC ISLANDS; PASTEURIZATION; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SAUDI ARABIA; SEROPREVALENCE; SPLENOMEGALY; THROMBOCYTOPENIA; UNITED STATES; UNSPECIFIED SIDE EFFECT;

ANIMALS; ASIA; BRUCELLOSIS; HUMANS; LIVESTOCK; MIDDLE EAST; NEGLECTED DISEASES; SOCIOECONOMIC FACTORS; ZOONOSES;

EID: 84883597277     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e3283638104     Document Type: Review

References (116)

1. Corbel MJ. Brucellosis in humans and animals. Geneva: WHO; 2006. http://www.who.int/csr/resources/publications/Brucellosis.pdf. [Accessed 28 March 2013]
2. Bruce D. Note on the discovery of a micro-organism in Malta fever. Practitioner 1887; 39:161-170.
3. Pappas G. The changing Brucella ecology: novel reservoirs, new threats. Int J Antimicrob Agents 2010; 36 (Suppl 1):S8-S11.
4. Buzgan T, Karahocagil MK, Irmak H, et al. Clinical manifestations and complications in 1028 cases of brucellosis: a retrospective evaluation and review of the literature. Int J Infect Dis 2010; 14:e469-e478.
5. Dean AS, Crump L, Greter H, et al. Clinical manifestations of human brucellosis: a systematic review and meta-analysis. PLoS Negl Trop Dis 2012; 6:e1929.
6. Lim PL, Han P, Chen LH, et al. Expatriates ill after travel: results from the Geosentinel Surveillance Network. BMC Infect Dis 2012; 12:386.
7. Bechtol D, Carpenter LR, Mosites E, et al. Brucella melitensis infection following military duty in Iraq. Zoonoses Public Health 2011; 58:489-492.
8. Pappas G, Papadimitriou P, Akritidis N, et al. The new global map of human brucellosis. Lancet Infect Dis 2006; 6:91-99.
9. Sayin-Kutlu S, Kutlu M, Ergonul O, et al. Laboratory-acquired brucellosis in Turkey. J Hosp Infect 2012; 80:326-330.
10. Pappas G, Panagopoulou P, Christou L, Akritidis N. Brucella as a biological weapon. Cell Mol Life Sci 2006; 63:2229-2236.
11. Hegazy YM, Moawad A, Osman S, et al. Ruminant brucellosis in the Kafr El Sheikh Governorate of the Nile Delta, Egypt: prevalence of a neglected zoonosis. PLoS Negl Trop Dis 2011; 5:e944.
12. BorbaMR, Stevenson MA, Goncalves VS, et al. Prevalence and risk-mapping of bovine brucellosis in Maranhao State, Brazil. Prev Vet Med 2013; 110:169-176.
13. Megersa B, Biffa D, Abunna F, et al. Seroprevalence of brucellosis and its contribution to abortion in cattle, camel, and goat kept under pastoral management in Borana, Ethiopia. Trop Anim Health Prod 2011; 43:651-656.
14. Gomo C, de Garine-Wichatitsky M, Caron A, Pfukenyi DM. Survey of brucellosis at the wildlife-livestock interface on the Zimbabwean side of the Great Limpopo Transfrontier Conservation Area. Trop Anim Health Prod 2012; 44:77-85.
15. Kashiwazaki Y, Ecewu E, Imaligat JO, et al. Epidemiology of bovine brucellosis by a combination of rose bengal test and indirect ELISA in the five districts of Uganda. J Vet Med Sci 2012; 74:1417-1422.
16. Asmare K, Megersa B, Denbarga Y, et al. A study on seroprevalence of caprine brucellosis under three livestock production systems in southern and central Ethiopia. Trop Anim Health Prod 2013; 45:555-560.
17. Roth F, Zinsstag J, Orkhon D, et al. Human health benefits from livestock vaccination for brucellosis: case study. Bull World Health Organ 2003; 81:867-876.
18. Perry BD, Grace D, Sones K. Current drivers and future directions of global livestock disease dynamics. Proc Natl Acad Sci USA 2011. [Epub ahead of print]
19. Bernues A, Manrique E, Maza MT. Economic evaluation of bovine brucellosis and tuberculosis eradication programmes in a mountain area of Spain. Prev Vet Med 1997; 30:137-149.
20. Haileselassie M, Kalayou S, Kyule M, et al. Effect of Brucella infection on reproduction conditions of female breeding cattle and its public health significance in Western Tigray, northern Ethiopia. Vet Med Int 2011; 2011:354943.
21. Olsen S, Tatum F. Bovine brucellosis. Vet Clin North Am Food Anim Pract 2010; 26:15-27.
22. World Health Organization. The control of neglected zoonotic diseases: a route to poverty alleviation. Reports of a joint WHO/DIFD-Animal Health Programme meeting with the participation of FAO and OIE, Geneva, 20-21 September 2005. Geneva: WHO; 2006. http://www.who.int/zoonoses/Report-Sept06.pdf. [Accessed 10 June 2012]
23. Franco MP, Mulder M, Gilman RH, Smits HL. Human brucellosis. Lancet Infect Dis 2007; 7:775-786.
24. Pappas G, Akritidis N, Bosilkovski M, Tsianos E. Brucellosis. N Engl J Med 2005; 352:2325-2336.
25. Cannella AP, Tsolis RM, Liang L, et al. Antigen-specific acquired immunity in human brucellosis: implications for diagnosis, prognosis, and vaccine development. Front Cell Infect Microbiol 2012; 2:1.
26. Jennings GJ, Hajjeh RA, Girgis FY, et al. Brucellosis as a cause of acute febrile illness in Egypt. Trans R Soc Trop Med Hyg 2007; 101:707-713.
27. Crump JA, Youssef FG, Luby SP, et al. Estimating the incidence of typhoid fever and other febrile illnesses in developing countries. Emerg Infect Dis 2003; 9:539-544.
28. Gargouri N, Walke H, Belbeisi A, et al. Estimated burden of human Salmonella, Shigella, and Brucella infections in Jordan, 2003-2004. Foodborne Pathog Dis 2009; 6:481-486.
29. Minas M, Minas A, Gourgulianis K, Stournara A. Epidemiological and clinical aspects of human brucellosis in Central Greece. Jpn J Infect Dis 2007; 60:362-366.
30. Avdikou I, Maipa V, Alamanos Y. Epidemiology of human brucellosis in a defined area of Northwestern Greece. Epidemiol Infect 2005; 133:905-910.
31. Guerrier G, Daronat JM, Morisse L, et al. Epidemiological and clinical aspects of human Brucella suis infection in Polynesia. Epidemiol Infect 2011; 139:1621-1625.
32. Lucero NE, Corazza R, Almuzara MN, et al. Human Brucella canis outbreak linked to infection in dogs. Epidemiol Infect 2010; 138:280-285.
33. Al-Tawfiq JA, Abukhamsin A. A 24-year study of the epidemiology of human brucellosis in a health-care system in Eastern Saudi Arabia. J Infect Public Health 2009; 2:81-85.
34. Abu Shaqra QM. Epidemiological aspects of brucellosis in Jordan. Eur J Epidemiol 2000; 16:581-584.
35. Yacoub AA, Bakr S, Hameed AM, et al. Seroepidemiology of selected zoonotic infections in Basra region of Iraq. East Mediterr Health J 2006; 12:112-118.
36. Bonfoh B, Kasymbekov J, Durr S, et al. Representative seroprevalences of brucellosis in humans and livestock in Kyrgyzstan. Ecohealth 2012; 9:132-138.
37. Abdullayev R, Kracalik I, Ismayilova R, et al. Analyzing the spatial and temporal distribution of human brucellosis in Azerbaijan (1995-2009) using spatial and spatio-temporal statistics. BMC Infect Dis 2012; 12:185.
38. Dean AS, Crump L, Greter H, et al. Global burden of human brucellosis: a systematic review of disease frequency. PLoS Negl Trop Dis 2012; 6:e1865.
39. Schelling E, Diguimbaye C, Daoud S, et al. Brucellosis and Q-fever seroprevalences of nomadic pastoralists and their livestock in Chad. Prev Vet Med 2003; 61:279-293.
40. Wang Y, Zhang W, Ke Y, et al. Human brucellosis, a heterogeneously distributed, delayed, and misdiagnosed disease in China. Clin Infect Dis 2013; 56:750-751.
41. Zhang WY, Guo WD, Sun SH, et al. Human brucellosis, inner Mongolia, China. Emerg Infect Dis 2010; 16:2001-2003.
42. Deqiu S, Donglou X, Jiming Y. Epidemiology and control of brucellosis in China. Vet Microbiol 2002; 90:165-182.
43. Doyle TJ, Bryan RT. Infectious disease morbidity in the US region bordering Mexico, 1990-1998. J Infect Dis 2000; 182:1503-1510.
44. Marder GSF, Czenik GE, Duran G. Seroprevalencia de brucelosis en hemodonantes del Banco de Sangre de Corrientes, Argentina [Seroprevalence of brucellosis in blood donors from Banco de Sangre de Corrientes, Argentina]. Revista Veterinaria 2005; 16:61-64.
45. Reddy EA, Shaw AV, Crump JA. Community-acquired bloodstream infections in Africa: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10:417-432.
46. Afifi S, Earhart K, Azab MA, et al. Hospital-based surveillance for acute febrile illness in Egypt: a focus on community-acquired bloodstream infections. Am J Trop Med Hyg 2005; 73:392-399.
47. Centers for Disease Control and Prevetion. 2012 Case Definitions: Nationally Notifiable Diseases and Conditions. Atlanta: CDC; 2012. http://wwwn. cdc.gov/nndss/document/2012-Case%20Definitions.pdf. [Accessed 27 December 2012]
48. Bouley AJ, Biggs HM, Stoddard RA, et al. Brucellosis among hospitalized febrile patients in northern Tanzania. Am J Trop Med Hyg 2012; 87:1105-1111.
49. Animut A, Mekonnen Y, Shimelis D, Ephraim E. Febrile illnesses of different etiology among outpatients in four health centers in Northwestern Ethiopia. Jpn J Infect Dis 2009; 62:107-110.
50. Manock SR, Jacobsen KH, de Bravo NB, et al. Etiology of acute undifferentiated febrile illness in the Amazon basin of Ecuador. Am J Trop Med Hyg 2009; 81:146-151.
51. Chow A, Robinson JL. Fever of unknown origin in children: a systematic review. World J Pediatr 2011; 7:5-10.
52. Ali-Eldin FA, Abdelhakam SM, Ali-Eldin ZA. Clinical spectrum of fever of unknown origin among adult Egyptian patients admitted to Ain Shams University Hospitals: a hospital based study. J Egypt Soc Parasitol 2011; 41:379-386.
53. Flores-Figueroa J, Okhuysen PC, von Sonnenburg F, et al. Patterns of illness in travelers visiting Mexico and Central America: the GeoSentinel experience. Clin Infect Dis 2011; 53:523-531.
54. Field V, Gautret P, Schlagenhauf P, et al. Travel and migration associated infectious diseases morbidity in Europe, 2008. BMC Infect Dis 2010; 10:330.
55. Rapp C, Aoun O, Ficko C, et al. Travel-related cerebro-meningeal infections: the 8-year experience of a French Infectious Diseases Unit. J Travel Med 2010; 17:1-7.
56. Freedman DO, Weld LH, Kozarsky PE, et al. Spectrum of disease and relation to place of exposure among ill returned travelers. N Engl J Med 2006; 354:119-130.
57. Leder K, Torresi J, Libman MD, et al. GeoSentinel surveillance of illness in returned travelers, 2007-2011. Ann Intern Med 2013; 158:456-468.
58. Vassallo DJ. The corps disease: brucellosis and its historical association with the Royal Army Medical Corps. J R Army Med Corps 1992; 138:140-150.
59. Swai ES, Schoonman L. Human brucellosis: seroprevalence and risk factors related to high risk occupational groups in Tanga Municipality, Tanzania. Zoonoses Public Health 2009; 56:183-187.
60. Ramos TR, Pinheiro Junior JW, Moura Sobrinho PA, et al. Epidemiological aspects of an infection by Brucella abortus in risk occupational groups in the microregion of Araguaina, Tocantins. Braz J Infect Dis 2008; 12:133-138.
61. John K, Fitzpatrick J, French N, et al. Quantifying risk factors for human brucellosis in rural northern Tanzania. PLoS One 2010; 5:e9968.
62. Earhart K, Vafakolov S, Yarmohamedova N, et al. Risk factors for brucellosis in Samarqand Oblast, Uzbekistan. Int J Infect Dis 2009; 13:749-753.
63. Kozukeev TB, Ajeilat S, Maes E, Favorov M. Risk factors for brucellosis: Leylek and Kadamjay districts, Batken Oblast, Kyrgyzstan, January-November, 2003. MMWR Morb Mortal Wkly Rep 2006; 55 (Suppl 1):31-34.
64. Makita K, Fevre EM, Waiswa C, et al. Spatial epidemiology of hospitaldiagnosed brucellosis in Kampala, Uganda. Int J Health Geogr 2011; 10:52.
65. Makita K, Fevre EM, Waiswa C, et al. How human brucellosis incidence in urban Kampala can be reduced most efficiently? A stochastic risk assessment of informally-marketed milk. PLoS One 2010; 5:e14188.
66. Akbayram S, Dogan M, Akgun C, et al. An analysis of children with brucellosis associated with pancytopenia. Pediatr Hematol Oncol 2011; 28:203-208.
67. Citak EC, Citak FE, Tanyeri B, Arman D. Hematologic manifestations of brucellosis in children: 5 years experience of an anatolian center. J Pediatr Hematol Oncol 2010; 32:137-140.
68. Troy SB, Rickman LS, Davis CE. Brucellosis in San Diego: epidemiology and species-related differences in acute clinical presentations. Medicine (Baltimore) 2005; 84:174-187.
69. Mete B, Kurt C, Yilmaz MH, et al. Vertebral osteomyelitis: eight years' experience of 100 cases. Rheumatol Int 2012; 32:3591-3597.
70. Oztekin O, Calli C, Adibelli Z, et al. Brucellar spondylodiscitis: magnetic resonance imaging features with conventional sequences and diffusionweighted imaging. Radiol Med 2010; 115:794-803.
71. Bozgeyik Z, Ozdemir H, Demirdag K, et al. Clinical and MRI findings of brucellar spondylodiscitis. Eur J Radiol 2008; 67:153-158.
72. Abo-shehada MN, Abu-Halaweh M. Seroprevalence of Brucella species among women with miscarriage in Jordan. East Mediterr Health J 2011; 17:871-874.
73. Karcaaltincaba D, Sencan I, Kandemir O, et al. Does brucellosis in human pregnancy increase abortion risk? Presentation of two cases and review of literature. J Obstet Gynaecol Res 2010; 36:418-423.
74. Colmenero JD, Reguera JM, Martos F, et al. Complications associated with Brucella melitensis infection: a study of 530 cases. Medicine (Baltimore) 1996; 75:195-211.
75. Zribi M, Ammari L, Masmoudi A, et al. Clinical manifestations, complications and treatment of brucellosis: 45-patient study. Pathol Biol (Paris) 2009; 57:349-352.
76. Kunda J, Fitzpatrick J, Kazwala R, et al. Health-seeking behaviour of human brucellosis cases in rural Tanzania. BMC Public Health 2007; 7:315.
77. Department of Communicable Disease and Response. WHO Recommended Surveillance Standards. 2nd ed. Geneva: WHO; 1999.
78. Araj GF. Update on laboratory diagnosis of human brucellosis. Int J Antimicrob Agents 2010; 36 (Suppl 1):S12-S17.
79. Yagupsky P. Detection of brucellae in blood cultures. J Clin Microbiol 1999; 37:3437-3442.
80. Diaz R, Casanova A, Ariza J, Moriyon I. The Rose Bengal Test in human brucellosis: a neglected test for the diagnosis of a neglected disease. PLoS Negl Trop Dis 2011; 5:e950.
81. El-Fekhfakh EA, Hassanain NA, El-Folly RF, El-Hariri H. Assessment of Rose Bengal test in diagnosing Egyptian human brucellosis. J Egypt Soc Parasitol 2011; 41:497-512.
82. Serra J, Vinas M. Laboratory diagnosis of brucellosis in a rural endemic area in northeastern Spain. Int Microbiol 2004; 7:53-58.
83. Shemesh AA, Yagupsky P. Limitations of the standard agglutination test for detecting patients with Brucella melitensis bacteremia. Vector Borne Zoonotic Dis (Larchmont, N Y) 2011; 11:1599-1601.
84. Fadeel MA, Hoffmaster AR, Shi J, et al. Comparison of four commercial IgM and IgG ELISA kits for diagnosing brucellosis. J Med Microbiol 2011; 60:1767-1773.
85. Centers for Disease Control and Prevention. Public health consequences of a false-positive laboratory test result for Brucella-Florida, Georgia, and Michigan, 2005. MMWR Morb Mortal Wkly Rep 2008; 57:603-605.
86. Matero P, Hemmila H, Tomaso H, et al. Rapid field detection assays for Bacillus anthracis, Brucella spp., Francisella tularensis and Yersinia pestis. Clin Microbiol Infect 2011; 17:34-43.
87. Marei A, Boghdadi G, Abdel-Hamed N, et al. Laboratory diagnosis of human brucellosis in Egypt and persistence of the pathogen following treatment. J Infect Dev Ctries 2011; 5:786-791.
88. Mizanbayeva S, Smits HL, Zhalilova K, et al. The evaluation of a user-friendly lateral flow assay for the serodiagnosis of human brucellosis in Kazakhstan. Diagn Microbiol Infect Dis 2009; 65:14-20.
89. Abdoel TH, Smits HL. Rapid latex agglutination test for the serodiagnosis of human brucellosis. Diagn Microbiol and Infect Dis 2007; 57:123-128.
90. Colmenero JD, Clavijo E, Morata P, et al. Quantitative real-time polymerase chain reaction improves conventional microbiological diagnosis in an outbreak of brucellosis due to ingestion of unpasteurized goat cheese. Diagn Microbiol Infect Dis 2011; 71:294-296.
91. Kumar S, Tuteja U, Sarika K, et al. Rapid multiplex PCR assay for the simultaneous detection of the Brucella genus, B. abortus, B. melitensis, and B. suis. J Microbiol Biotechnol 2011; 21:89-92.
92. Winchell JM, Wolff BJ, Tiller R, et al. Rapid identification and discrimination of Brucella isolates by use of real-time PCR and high-resolution melt analysis. J Clin Microbiol 2010; 48:697-702.
93. Queipo-Ortuno MI, Colmenero JD, Bermudez P, et al. Rapid differential diagnosis between extrapulmonary tuberculosis and focal complications of brucellosis using a multiplex real-time PCR assay. PLoS One 2009; 4:e4526.
94. Yousefi-Nooraie R, Mortaz-Hejri S, Mehrani M, Sadeghipour P. Antibiotics for treating human brucellosis. Cochrane Database Syst Rev 2012; 10: CD007179.
95. Skalsky K, Yahav D, Bishara J, et al. Treatment of human brucellosis: systematic review and meta-analysis of randomised controlled trials. BMJ 2008; 336:701-704.
96. Hasanjani Roushan MR, Mohraz M, Hajiahmadi M, et al. Efficacy of gentamicin plus doxycycline versus streptomycin plus doxycycline in the treatment of brucellosis in humans. Clin Infect Dis 2006; 42:1075-1080.
97. Hashemi SH, Gachkar L, Keramat F, et al. Comparison of doxycyclinestreptomycin, doxycycline-rifampin, and ofloxacin-rifampin in the treatment of brucellosis: a randomized clinical trial. Int J Infect Dis 2012; 16:e247-e251.
98. Keramat F, Ranjbar M, Mamani M, et al. A comparative trial of three therapeutic regimens: ciprofloxacin-rifampin, ciprofloxacin-doxycycline and doxycycline-rifampin in the treatment of brucellosis. Trop Doct 2009; 39:207-210.
99. Ranjbar M, Keramat F, Mamani M, et al. Comparison between doxycyclinerifampin-amikacin and doxycycline-rifampin regimens in the treatment of brucellosis. Int J Infect Dis 2007; 11:152-156.
100. Roushan MR, AmiriMJ, Janmohammadi N, et al. Comparison of the efficacy of gentamicin for 5 days plus doxycycline for 8 weeks versus streptomycin for 2 weeks plus doxycycline for 45 days in the treatment of human brucellosis: a randomized clinical trial. J Antimicrob Chemother 2010; 65:1028-1035.
101. Solis Garcia del Pozo J, Solera J. Systematic review and meta-analysis of randomized clinical trials in the treatment of human brucellosis. PLoS One 2012; 7:e32090.
102. Ariza J, Bosilkovski M, Cascio A, et al. Perspectives for the treatment of brucellosis in the 21st century: the Ioannina recommendations. PLoS Med 2007; 4:e317.
103. Bayram Y, Korkoca H, Aypak C, et al. Antimicrobial susceptibilities of Brucella isolates from various clinical specimens. Int J Med Sci 2011; 8:198-202.
104. Maves RC, Castillo R, Guillen A, et al. Antimicrobial susceptibility of Brucella melitensis isolates in Peru. Antimicrob Agents Chemother 2011; 55:1279-1281.
105. Sayan M, Kilic S, Uyanik MH. Epidemiological survey of rifampicin resistance in clinic isolates of Brucella melitensis obtained from all regions of Turkey. J Infect Chemother 2012; 18:41-46.
106. Sayan M, Yumuk Z, Dundar D, et al. Rifampicin resistance phenotyping of Brucella melitensis by rpoB gene analysis in clinical isolates. J Chemother 2008; 20:431-435.
107. Valdezate S, Navarro A, Medina-Pascual MJ, et al. Molecular screening for rifampicin and fluoroquinolone resistance in a clinical population of Brucella melitensis. J Antimicrob Chemother 2010; 65:51-53.
108. Zinsstag J, Schelling E, Roth F, et al. Human benefits of animal interventions for zoonosis control. Emerg Infect Dis 2007; 13:527-531.
109. Perkins SD, Smither SJ, Atkins HS. Towards a Brucella vaccine for humans. FEMS Microbiol Rev 2010; 34:379-394.
110. Godfroid J, Al Dahouk S, Pappas G, et al. A 'One Health' surveillance and control of brucellosis in developing countries: moving away from improvisation. Comp Immunol Microbiol Infect Dis 2013; 36:241-248.
111. Godfroid J, Scholz HC, Barbier T, et al. Brucellosis at the animal/ecosystem/human interface at the beginning of the 21st century. Prev Vet Med 2011; 102:118-131.
112. McDermott JJ, Arimi SM. Brucellosis in sub-Saharan Africa: epidemiology, control and impact. Vet Microbiol 2002; 90:111-134.
113. Marcotty T, Matthys F, Godfroid J, et al. Zoonotic tuberculosis and brucellosis in Africa: neglected zoonoses or minor public-health issues? The outcomes of a multidisciplinary workshop. Ann Trop Med Parasitol 2009; 103:401-411.
114. Renukaradhya GJ, Isloor S, Rajasekhar M. Epidemiology, zoonotic aspects, vaccination and control/eradication of brucellosis in India. Vet Microbiol 2002; 90:183-195.
115. Ward D, Jackson R, Karomatullo H, et al. Brucellosis control in Tajikistan using Rev 1 vaccine: change in seroprevalence in small ruminants from 2004 to 2009. Vet Rec 2012; 170:100.
116. Haydon DT, Cleaveland S, Taylor LH, Laurenson MK. Identifying reservoirs of infection: a conceptual and practical challenge. Emerg Infect Dis 2002; 8:1468-1473.